During a live event, Andrew Brunner, MD, and participants discussed escalating therapy in luspatercept-refractory LR-MDS. For patients with lower-risk myelodysplastic syndromes (LR-MDS) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results